Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma

HIGHLIGHTS

• who: Shixian Liu from the University of Siena, Italy have published the research work: Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma, in the Journal: (JOURNAL)
• what: The aim of this study was to assess the cost-effectiveness of nivolumab combination therapy as first-line management for advanced ESCC patients in China.
• how: The estimated scale (l) and shape (g) parameters of the fitting model are presented in Table 1. As the CheckMate 648 trial did not report the utility values of different . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.